455 related articles for article (PubMed ID: 9153534)
1. CAG repeat number governs the development rate of pathology in Huntington's disease.
Penney JB; Vonsattel JP; MacDonald ME; Gusella JF; Myers RH
Ann Neurol; 1997 May; 41(5):689-92. PubMed ID: 9153534
[TBL] [Abstract][Full Text] [Related]
2. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
[TBL] [Abstract][Full Text] [Related]
3. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion.
Margolis RL; O'Hearn E; Rosenblatt A; Willour V; Holmes SE; Franz ML; Callahan C; Hwang HS; Troncoso JC; Ross CA
Ann Neurol; 2001 Sep; 50(3):373-80. PubMed ID: 11558794
[TBL] [Abstract][Full Text] [Related]
4. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease.
Furtado S; Suchowersky O; Rewcastle B; Graham L; Klimek ML; Garber A
Ann Neurol; 1996 Jan; 39(1):132-6. PubMed ID: 8572659
[TBL] [Abstract][Full Text] [Related]
5. Regional specificity of brain atrophy in Huntington's disease.
Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E
Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201
[TBL] [Abstract][Full Text] [Related]
6. Trinucleotide repeat length and rate of progression of Huntington's disease.
Illarioshkin SN; Igarashi S; Onodera O; Markova ED; Nikolskaya NN; Tanaka H; Chabrashwili TZ; Insarova NG; Endo K; Ivanova-Smolenskaya IA
Ann Neurol; 1994 Oct; 36(4):630-5. PubMed ID: 7944295
[TBL] [Abstract][Full Text] [Related]
7. Does CAG repeat number predict the rate of pathological changes in Huntington's disease?
Rosenblatt A; Margolis RL; Becher MW; Aylward E; Franz ML; Sherr M; Abbott MH; Lian KY; Ross CA
Ann Neurol; 1998 Oct; 44(4):708-9. PubMed ID: 9778276
[No Abstract] [Full Text] [Related]
8. Molecular analysis of the Huntington's disease gene in New Zealand.
Whitefield JE; Williams L; Snow K; Dixon J; Winship I; Stapleton PM; Faull RM; Love DR
N Z Med J; 1996 Feb; 109(1015):27-30. PubMed ID: 8606810
[TBL] [Abstract][Full Text] [Related]
9. [Huntington's disease: trinucleotide disease or polyglutamine disease?].
Ide K; Nukina N; Kanazawa I
Rinsho Shinkeigaku; 1995 Dec; 35(12):1540-1. PubMed ID: 8752457
[TBL] [Abstract][Full Text] [Related]
10. Huntington's disease - neuropathology.
Vonsattel JP; Keller C; Cortes Ramirez EP
Handb Clin Neurol; 2011; 100():83-100. PubMed ID: 21496571
[TBL] [Abstract][Full Text] [Related]
11. Variation of selective gray and white matter atrophy in Huntington's disease.
Jech R; Klempír J; Vymazal J; Zidovská J; Klempírová O; Růzicka E; Roth J
Mov Disord; 2007 Sep; 22(12):1783-9. PubMed ID: 17579363
[TBL] [Abstract][Full Text] [Related]
12. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes.
Stevanin G; Fujigasaki H; Lebre AS; Camuzat A; Jeannequin C; Dode C; Takahashi J; San C; Bellance R; Brice A; Durr A
Brain; 2003 Jul; 126(Pt 7):1599-603. PubMed ID: 12805114
[TBL] [Abstract][Full Text] [Related]
13. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum.
Butterworth NJ; Williams L; Bullock JY; Love DR; Faull RL; Dragunow M
Neuroscience; 1998 Nov; 87(1):49-53. PubMed ID: 9722140
[TBL] [Abstract][Full Text] [Related]
14. The association of CAG repeat length with clinical progression in Huntington disease.
Rosenblatt A; Liang KY; Zhou H; Abbott MH; Gourley LM; Margolis RL; Brandt J; Ross CA
Neurology; 2006 Apr; 66(7):1016-20. PubMed ID: 16606912
[TBL] [Abstract][Full Text] [Related]
15. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.
Andrew SE; Goldberg YP; Kremer B; Telenius H; Theilmann J; Adam S; Starr E; Squitieri F; Lin B; Kalchman MA
Nat Genet; 1993 Aug; 4(4):398-403. PubMed ID: 8401589
[TBL] [Abstract][Full Text] [Related]
16. Parameter-based assessment of spatial and non-spatial attentional deficits in Huntington's disease.
Finke K; Bublak P; Dose M; Müller HJ; Schneider WX
Brain; 2006 May; 129(Pt 5):1137-51. PubMed ID: 16504973
[TBL] [Abstract][Full Text] [Related]
17. [Expansion of triplet repeat and neurodegenerative disorders].
Kanazawa I
Rinsho Shinkeigaku; 1994 Dec; 34(12):1224-6. PubMed ID: 7774118
[TBL] [Abstract][Full Text] [Related]
18. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat.
Ruocco HH; Lopes-Cendes I; Li LM; Santos-Silva M; Cendes F
Braz J Med Biol Res; 2006 Aug; 39(8):1129-36. PubMed ID: 16906288
[TBL] [Abstract][Full Text] [Related]
19. The relationship between CAG repeat length and clinical progression in Huntington's disease.
Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
[TBL] [Abstract][Full Text] [Related]
20. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.
Langbehn DR; Brinkman RR; Falush D; Paulsen JS; Hayden MR;
Clin Genet; 2004 Apr; 65(4):267-77. PubMed ID: 15025718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
